Carnorin (Drops) Instructions for Use

Marketing Authorization Holder

Belmedpreparaty RUP (Republic of Belarus)

ATC Code

S01XA (Other preparations for the treatment of eye diseases)

Dosage Form

Carnorin

5% Eye drops: 5 or 10 ml bottle with dropper cap

Dosage Form, Packaging, and Composition

Eye drops transparent, colorless or with a yellow-green tint.

Excipients: sodium chloride – 2.17 mg, benzalkonium chloride – 0.08 mg, water for injections – up to 1 ml.

5 ml – bottles (1) with a dropper cap – cardboard packs.
10 ml – bottles (1) with a dropper cap – cardboard packs.

Clinical-Pharmacological Group

A drug that stimulates regeneration processes for topical use in ophthalmology

Pharmacotherapeutic Group

Metabolic agent

Pharmacological Action

Carnosine is a histidine-containing dipeptide, one of the natural products of metabolism in the human body.

It is a biologically active dipeptide that affects metabolic processes: glycolysis, oxidative phosphorylation.

The mechanism of action is due to its antioxidant and membrane-protective effects.

Carnosine inhibits lipid peroxidation, enhances antioxidant protection, and increases the body’s resistance to the effects of various pathological factors in oxygen-dependent conditions.

Carnosine has an accelerating effect on the processes of oxidative phosphorylation.

It enhances ATP synthesis, increases the Ca²⁺/ATP ratio in impaired active transport of calcium ions in the sarcoplasmic reticulum, and increases the efficiency of active transport of sodium and potassium ions.

It accelerates the healing of defects and damage to the corneal epithelium of traumatic, chemical, radiation, infectious, and trophic etiology.

It has pronounced therapeutic efficacy in the complex treatment of trophic keratitis, postherpetic epitheliopathy, primary and secondary corneal dystrophy, recurrent corneal erosion, and bullous keratopathy.

Carnosine, as part of complex therapy, accelerates the healing of ulcerative keratopathy of the cornea in herpesvirus and bacterial infections, and dry keratoconjunctivitis.

Pharmacokinetics

When using carnosine eye drops, the active substance does not enter the systemic circulation in biologically active concentrations.

The therapeutic concentration is achieved with the local application of the drug in the tissues and biological fluids of the eye.

Carnosine is completely metabolized in the human body and does not accumulate in organs and tissues.

Indications

As part of complex therapy

• Keratopathy of various etiologies;
• Ulcerative keratitis;
• Metabolic diseases of the corneal tissues.

ICD codes

Dosage Regimen

Instill the drops topically into the conjunctival sac.

Apply 1 to 3 drops into the affected eye(s).

Administer the drops 4 to 6 times daily.

The standard treatment duration is 1 to 3 weeks.

Adjust the exact duration based on the clinical course of the disease.

Follow the prescribed regimen determined by your physician.

Remove contact lenses before instillation.

Reinsert lenses no sooner than 15 minutes after application.

Avoid allowing the dropper tip to contact any surface to prevent contamination.

If you experience significant burning or vision changes, consult your doctor promptly.

Adverse Reactions

Burning in the eye (usually does not require discontinuation).

Contraindications

• Hypersensitivity to carnosine or other components of the drug;
• Children under 18 years of age (efficacy and safety have not been established).

With caution in patients with a burdened allergic history.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation (efficacy and safety have not been established). Breastfeeding should be discontinued during treatment.

Pediatric Use

Contraindicated in children under 18 years of age.

Special Precautions

The preservative contained in the eye drops can be deposited on soft contact lenses (causing a change in their color) and have an irritating effect on the eye tissues when they are used.

Contact lenses should be removed before instillation and put back on after 15 minutes.

Effect on the ability to drive vehicles and operate other potentially dangerous mechanisms

Patients who experience temporary changes in visual clarity after using the drug are not recommended to drive vehicles or operate other potentially dangerous mechanisms.

Overdose

Cases of overdose with Carnorin have not been described.

Drug Interactions

No negative manifestations have been described when using Carnorin in case of simultaneous use with other drugs.

It can be used in complex therapy together with idoxuridine, acyclovir eye ointment, dexamethasone.

Storage Conditions

At a temperature from 15 to 25°C (77°F). The bottle after opening should be stored in a place protected from light at a temperature from 15 to 25°C (77°F).

Shelf Life

The shelf life is 3 years.

Dispensing Status

By prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.